Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Kswdeluxon Apr 28, 2022 3:09pm
186 Views
Post# 34639952

RE:RE:Updated corporate presentation dated April 2022

RE:RE:Updated corporate presentation dated April 2022 I agree, anything in the books right now until after Bracelet topline data seems to be a none event that will not effect SP.

The only wild card I see any possible in is what comes out of is the AWARE-1 Q2 2022 release if it even comes out prior to June 1. But even at that I doubt anything significant will come from it that will save the warranty.

I also know someone who suggested to ONC an extension on then warrants based on the unforeseen conditions of COVID delaying enrollment, thus is would not be an unreasonable response to extend the warrants based on COVID as everything else in the world right now seems to be delayed by COVID. But no response.
<< Previous
Bullboard Posts
Next >>